News
06-17-2021, 10:41 PM
In a new study by researchers at Yale Cancer Center, combining the immunotherapy drug durvalumab and PARP-inhibitor olaparib with chemotherapy improved response to treatment for women with high-risk, HER2-negative breast cancer, including a subset of estrogen receptor positive cancers.
More... (https://www.news-medical.net/news/20210618/Adding-immune-oncology-drug-to-chemotherapy-improves-response-in-subset-of-breast-cancer-patients.aspx)
More... (https://www.news-medical.net/news/20210618/Adding-immune-oncology-drug-to-chemotherapy-improves-response-in-subset-of-breast-cancer-patients.aspx)